EDWARD MYERS: Open Payments
NPI 1568851020 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$485 in 25 payments from 9 companies in 2025. Trend: 2023 $858 · 2024 $558 · 2025 $485
Food & beverage: $485
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $197 |
| Boston Scientific Corporation | 1 | $138 |
| Melinta Therapeutics, LLC | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| SANOFI-AVENTIS U.S. LLC | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Gilead Sciences, Inc. | 1 | $21 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Amgen Inc. | 1 | $14 |
Products named: Intracept, VRAYLAR, QULIPTA, Rezzayo, CAPLYTA, DALVANCE, TZIELD, FANAPT.
Industry payments across LA — which companies pay providers there.
